PDS Biotech rises on plans to start late-stage study for lead therapy combination

PDS Biotechnology

30/03/2023 14:44

** Shares on cancer immunotherapy developer PDS
Biotechnology Corp  PDSB.O  rise 1.4% to $6.1
    ** Co plans to initate late-stage study investigating the
combination of its lead candidate PDS0101 and Merck & Co's
 MRK.N  Keytruda in Q4 2023
    ** The trial will evaluate the combination compared to
keytruda monotherapy for a type of head and neck cancer
    ** Co plans to submit an amended application to the U.S. FDA
in Q3 2023 
    ** PDS0101, co's lead candidate, is a novel investigational
human papilloma virus (HPV)-targeted immunotherapy
    ** Despite session's gains, stock down ~54% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))